Background. Genetic factors contributing to the development of IgA nephropathy remain to be elucidated. Methods. The present multicenter cross-sectional case-control study measured genotype frequencies of 65 atherosclerotic disease-related gene polymorphisms in 230 Japanese patients with IgA nephropathy and 262 apparently healthy volunteers with estimated glomerular filtration rate (eGFR) !60 mL/min/1.73 m 2 and negative or trace proteinuria and hematuria by dipstick test [non-chronic kidney disease (CKD) participants]. Clinical characteristics at kidney biopsy of patients with IgA nephropathy and those at the study recruitment of non-CKD participants were included as covariates in multivariate logistic regression models. Results. Among 31 gene polymorphisms with !5% of minor genotype in non-CKD participants, methionine synthase MTR A2756G (D919G) was significantly associated with IgA nephropathy using v 2 test even after controlling for family-wise error rate by the method of Bonferroni (P ¼ 0.044). A multivariate nonconditional logistic regression model identified MTR A2756G as a significant contributor of IgA nephropathy [2756AG and GG versus AA, odds ratio 0.42 (95% confidence interval 0.25-0.69) and 0.21 (95% confidence interval 0.06-0.68), P trend < 0.001]. After each patient with IgA nephropathy was randomly matched to a non-CKD participant on age (65 years), gender, mean arterial pressure (65 mmHg) and eGFR (65 mL/min/1.73 m 2 ), a multivariate conditional logistic regression model also verified their significant association [odds ratio 0.42 (95% confidence interval 0.18-1.00) and odds ratio 0.09 (95% confidence interval 0.01-0.73), P trend ¼ 0.004]. MTR A2756G was not associated with slope of eGFR (mL/min/1.73 m 2 /year) in 230 patients with IgA nephropathy.
Introduction
IgA nephropathy is the most common primary glomerulonephritis in the world [1] [2] [3] , which progresses to end-stage renal disease (ESRD) within 10 years of diagnosis in~15 to 25% of the patients [4] . Besides environmental factors, a large number of studies suggested that genetic factors contributed to the pathogenesis of IgA nephropathy [5] , which is characterized by the deposition of IgA in the glomerular mesangium along with proliferation of the mesangial cells and accumulation of the mesangial matrix. Among the clinical evidence for the genetic contribution to the development of IgA nephropathy came from familial aggregation of IgA nephropathy. Several genome-wide studies of multiplex families of IgA nephropathy successfully identified several loci with significant linkage on 2q36 [6] , 4q26-31 [7] , 6q22-23 (IgAN1) [8] and 17q12-22 [7] . When it comes to sporadic IgA nephropathy, a large number of studies suggested associations between multiple gene polymorphisms and IgA nephropathy, usually using a candidate gene approach [5, 9] . The majority of the studies failed to verify that the gene polymorphisms of interest might have contributed to development, but not progression, of IgA nephropathy because of a lack of data of the renal outcome during long-term follow-up and insufficient clinical data of the control participants, usually only age and gender.
IgA1 molecule with undergalactosylation of O-glycans in its hinge region, also referred to as aberrantly glycosylated IgA1 [10, 11] , is now regarded as the central factor of pathogenesis of IgA nephropathy [12, 13] . Several studies revealed that aberrantly glycosylated IgA1 had higher biological effects, including higher affinity for the mesangial cells [14, 15] , increased or decreased production of inflammatory mediators in mesangial cells [15] [16] [17] [18] [19] [20] and enhanced proliferation and apoptosis of the mesangial cells [20] [21] [22] . It is unlikely that the presence of aberrantly glycosylated IgA1 is, however, sufficient to develop IgA nephropathy since asymptomatic mesangial IgA deposition was relatively common (16%) in the donor kidney for kidney transplantation [23] and the serum aberrantly glycosylated IgA1 was at a significantly higher level even in the first-degree relatives of the patients with IgA nephropathy, who had no clinical manifestation of IgA nephropathy [24, 25] . The patients with the higher serum level of aberrantly glycosylated IgA1 and its glomerular deposition potentially needs a'second hit' to bring asymptomatic glomerular IgA1 deposition to clinically symptomatic, namely, proteinuric IgA nephropathy [9, 26] . One of the candidates for second hit is oxidative stress [26] . As oxidative stress plays a pivotal role in atherosclerotic diseases, the atherosclerotic disease-related gene polymorphisms may be associated with the second hit for the development of IgA nephropathy.
The purpose of the present study was to identify the gene polymorphisms contributing to the development of IgA nephropathy among 65 atherosclerotic disease-related gene polymorphisms using a candidate gene approach. Long-term observational date [median 9.4 (interquartile range 5.9-12.7) years] in 230 patients with IgA nephropathy and the details of clinical characteristics of 262 control participants without chronic kidney disease (CKD) enabled us to distinguish between gene polymorphisms associated with development of IgA nephropathy and those with progression. The present study potentially provides a new insight into the development of IgA nephropathy.
Materials and methods

Participants
The present study was a cross-sectional study comparing the genotype frequencies of atherosclerotic disease-related gene polymorphisms between patients with IgA nephropathy and non-CKD participants.
Genetic and clinical data of 232 patients with IgA nephropathy were retrieved from the previous study, the Polymorphism REsearch to DIstiguish genetic factors Contributing To progression of IgA Nephropathy (PREDICT-IgAN) [27] . Briefly, 1132 patients aged at least 15 years were diagnosed with IgA nephropathy by kidney biopsy in Osaka University Hospital, Osaka General Medical Center and Osaka Rosai Hospital in Osaka prefecture, Japan, between January 1990 and 2005. Among 482 patients who visited these hospitals between April 2006 and March 2008, 429 patients were enrolled in PREDICT-IgAN and their venous blood was collected for identification of the atherosclerotic disease-related gene polymorphisms. After excluding two patients with estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m 2 at kidney biopsy (calculation of eGFR is described below in detail) and two patients with missing data, the present study included 230 patients aged between 25 and 50 years at kidney biopsy, who were assumed to be more typically predisposed to genetic factors of IgA nephropathy compared with the older patients.
A total of 315 apparently healthy hospital employees aged between 25 and 50 years, who were recruited in the previous studies [28] [29] [30] , provided the venous blood for identification of atherosclerotic diseaserelated gene polymorphisms. Among 289 non-CKD participants with negative (À) or trace (AE) for both proteinuria and hematuria and eGFR !60 mL/min/1.73m 2 , 262 participants were included as the controls, after excluding 24 participants who received antihypertensive or lipid-lowering agents and 3 participants with missing data.
The study protocol of the present study was approved by the ethical committees in Osaka University, Osaka General Medical Center and Osaka Rosai Hospital.
Measurements
Genotypes of 65 atherosclerotic disease-related gene polymorphisms were available in patients with IgA nephropathy and non-CKD participants (Table 1) , which was determined with a fluorescence-or colorimetrybased allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described by Yamada et al. [31] in detail.
Clinical data were obtained at kidney biopsy in patients with IgA nephropathy and at donation of the venous blood in non-CKD participants, including age, gender, body mass index [¼ body weight (kg)/height 2 (m 2 )], serum creatinine, eGFR, proteinuria and hematuria by dipstick, urinary protein (only in patients with IgA nephropathy) and use of antihypertensive and lipid-lowering agents. Serum creatinine was measured using the enzymatic method in 185 (79.7%) of 230 patients with IgA nephropathy, whereas using the Jaffé method in 47 patients (20.4%) diagnosed with IgA nephropathy before November 1995 in a single facility. Using the sera from 648 patients in the facility, the correlation coefficient r between creatinine values measured using the Jaffe method and the enzymatic method was 0.998 and the least square method determined the predictive equation: creatinine (enzymatic method) ¼ 0.94 3 creatinine (Jaffé method) À 0.25. Consequently, creatinine values for 47 patients diagnosed with IgA nephropathy before November 1995 were converted using this equation [32] . Accordingly, GFR of all 232 patients with IgA nephropathy was estimated using 194 3 serum creatinine (enzymatic method, mg/dL) À1.094 3 age (year) À0.287 3 0.739 (if female) [33] . Because serum creatinine of 253 non-CKD participants was measured using Jaffe method, their GFR was estimated using 186 3 serum creatinine (Jaffe method, mg/dL) À1.154 3 age (year) À0.203 3 0.742 (if female) [34] . Observational period of the patients with IgA nephropathy was defined as time from kidney biopsy to the development of ESRD or the last measurement of the serum creatinine before September 2009, whichever came first. Slope of eGFR (mL/min/1.73 m 2 /year) was calculated based on eGFR at kidney biopsy and that at the end of observational period.
Statistics
Differences in clinical characteristics between non-CKD participants and patients with IgA nephropathy were compared using unpaired t-tests, Wilcoxon's rank-sum tests and v 2 tests, appropriately, and those between 69 matched pairs of IgA nephropathy and non-CKD participants were using paired t-tests, Wilcoxon's signed rank tests and McNemar's tests, appropriately.
To identify the gene polymorphisms associated with development of IgA nephropathy, genotype frequencies of the gene polymorphisms in Hardy-Weinberg equilibrium with at least 5% of minor genotype in non-CKD participants were compared between 230 patients with IgA nephropathy and 262 non-CKD participants using v 2 tests. The method of Bonferroni was used to control a family-wise error rate due to multiple comparisons. Namely, given N hypothesis of interests, N 3 P-value (adjusted P-value) was compared with a level. Odds ratio for IgA nephropathy of each genotype of the gene polymorphisms was calculated using univariate logistic regression models and multivariate logistic regression models adjusting for clinically relevant factors such as age, gender, body mass index, mean arterial blood pressure and eGFR. P-value for trend test examined a dose-dependent association between genotypes and odds ratios (major homozygote, heterozygote and minor homozygote were coded as 0, 1 and 2, respectively). As sensitivity analysis, an association between each genotype of the gene polymorphisms and IgA nephropathy was assessed in univariate and multivariate logistic regression models after excluding 25 (9.5%) non-CKD participants with trace for urinary protein or hematuria by dipstick test, who might have subclinical IgA nephropathy.
To control substantial differences in age, gender, mean arterial blood pressure and eGFR between 230 patients with IgA nephropathy and 262 non-CKD participants, each patient with IgA nephropathy without antihypertensive and lipid-lowering agents was randomly matched to a non-CKD patient on age (AE5 years), gender, mean arterial pressure (AE5 mmHg) and eGFR (AE5 mL/min/1.73 m 2 ) without replacement. 
Continued
Conditional logistic regression models were used to assess associations between the gene polymorphisms and the IgA nephropathy, adjusting for age, body mass index, mean arterial pressure and eGFR. Unadjusted powers to detect genotype relative risk (GRR) of 2.0 for IgA nephropathy at a ¼ 0.05 level in multiplicative, additive, dominant and recessive models were calculated using CaTS Power Calculator [35] in all gene polymorphisms. If f 0 , f 1 and f 2 are the probabilities of being affected for participants with 0, 1 or 2 copies of the risk allele, then GRR of multiplicative, additive, dominant and recessive models were as follows:
In 31 gene polymorphism with !5% of minor homozygotes, the adjusted powers at a ¼ 1.61 3 10 3 (¼ 0.05/31) level controlling for family-wise error rate were also calculated.
The candidate gene polymorphisms might contribute to urinary protein, not to the development of IgA nephropathy. To verify whether the candidate gene polymorphisms were associated with IgA nephropathy, and not with urinary protein, we compared the urinary protein level in each genotype of the candidate gene polymorphisms in the patients with IgA nephropathy using trend test [36] . The candidate gene polymorphisms were potentially associated with progression of IgA nephropathy, in addition to its development. To assess whether the candidate gene polymorphisms were renal prognostic factors of IgA nephropathy, associations between the genotypes of the candidate gene polymorphisms and slopes of eGFR were compared in patients with IgA nephropathy.
Normally distributed continuous variables were expressed as mean AE SD and non-normally distributed continuous variables as median (interquartile range). Categorical variables were expressed as numbers (proportions). All statistical analyses were performed using STATA version 11 (STATA Corp, College Station, TX) if not specified.
Results
Clinical characteristics of 230 patients with IgA nephropathy and 262 non-CKD participants were described in Table 2 . Patients with IgA nephropathy were female predominant, hypertensive and lower in eGFR, compared with non-CKD participants, despite insignificant differences in age and body mass index. Median (interquartile range) of urinary protein in the patients with IgA nephropathy at kidney biopsy was 0.54 (0.26-1.12) g/day.
Frequency of minor genotypes in non-CKD participants was !5% in 31 of 65 atherosclerotic disease-related gene polymorphisms (Table 1) . Among these 31 gene polymorphisms, unadjusted powers in multiplicative, additive, dominant and recessive models were !80% in 31 (100%), 30 (96.8%), 8 (25.8%) and 21 (67.7%) gene polymorphisms, respectively. Although P-values for HardyWeinberg equilibrium were <0.05 in ACE I/D, IL-18 C-607A and LTA A252G in non-CKD participants, no obvious Hardy-Weinberg disequilibrium was observed after controlling family-wise error rates by the method of Bonferroni (Table 3) . Thus, associations between 31 gene polymorphisms and development of IgA nephropathy were subsequently assessed using v 2 test and odds ratios of genotypes were calculated using univariate logistic regression models. Among three gene polymorphisms with P < 0.05 for v 2 test, namely, MTR A2756G (D919G), ADIPOQ T94G and ACE I/D, only MTR A2756G was significantly associated with IgA nephropathy even after adjustment by the method of Bonferroni. Adjusted powers controlling for family-wise error rate were !80% in 30 (96.8%), 13 (41.9%), 0 (0.0%) and 0 (0.0%) in multiplicative, additive, dominant and recessive models, respectively. Univariate logistic regression models demonstrated that MTR A2756G [odds ratio for AG (versus AA) 0.52 (95% Table 1 . MTR, methionine synthase; p22phox, nicotinamide adenine dinucleotoide phosphate oxidase p22phox subunit; PAI-1, plasminogen activator inhibitor-1; PGC-1a, peroxisome proliferation-activated receptor c coactivator-a; PPARc, peroxisome proliferation-activated receptor c; RAGE, receptor for advanced glycation end products; SELE, E-selection; TM, thrombomodulin; TNFA, tumor necrosis factor-a; TPO, thrombopoietin; TSP-4, thrombospondin-4; VEGF, vascular endothelial growth factor; vWF, von Willebrand factor. To control remarkable differences between clinical characteristics of patients with IgA nephropathy and non-CKD participants, each patient with IgA nephropathy was matched with a non-CKD participant on age (AE5 years), gender, mean arterial pressure (AE5 mmHg) and eGFR (AE5 mL/min/1.73 m 2 ). Clinical characteristics of 69 matched pairs of 69 patients with IgA nephropathy and 69 non-CKD participants were not significantly different, except MTR A2756G (P ¼ 0.003 for 2756AA versus AG/GG and P ¼ 0.011 for 2756AA/AG versus GG) ( Table 5 ). Univariate and multivariate conditional logistic regression models identified a significant dose-dependent association between MTR A2756G and IgA nephropathy (P trend ¼ 0.002 and 0.004 in univariate and multivariate models, respectively) ( Table 6 ).
Since the presence of proteinuria was also a distinct difference between patients with IgA nephropathy and non-CKD participants besides the histopathologic diagnosis of IgA nephropathy, MTR A2756G might be associated with proteinuria. We subsequently assessed a dose-dependent association between MTR A2756G and urinary protein in 232 patients with IgA nephropathy. Medians (interquartile range) of urinary protein in MTR 2756AA, AG and GG were 0.53 (0.24-1.11), 0.62 (0.30-1.14) and 0.37 (0.16-0.70) g/day, respectively, demonstrating an insignificant dose-dependent association between MTR A2756G and urinary protein (P trend ¼ 0.722) ( Table 7) . Univariate and multivariate regression models also failed in a significant association between MTR A2756G and urinary protein (P trend ¼ 0.861 and 0.931 in univariate and multivariate models, respectively). These results suggested that MTR A2756G hardly contributed to proteinuria.
Finally, we examined that MTR A2756G was associated with progression of IgA nephropathy defined by slope of eGFR. During median 9.5 (interquartile range 5.9-12.7) year of observational period, the slopes of eGFR in MTR 2756AA, AG and GG were À1.73 AE 3.20, À2.25 AE 5.46 and À2.05 AE 1.83 mL/min/1.73 m 2 /year, respectively, suggesting an insignificant association between MTR A2756G and slope of eGFR (P trend ¼ 0.993) ( Table 8 ). Univariate and multivariate regression models did not identify MTR A2756G as a predictor of slope of eGFR (P trend ¼ 0.423 and 0.459 in univariate and multivariate regression models, respectively).
Discussion
The present study identified MTR A2756G as a genetic contributor to the development of IgA nephropathy among 65 atherosclerotic disease-related gene polymorphisms. Methionine synthase is one of the key enzymes in metabolism of homocysteine, which is a potential predictor of cardiovascular diseases [37] and CKD [38] . No studies identified MTR gene polymorphisms as genetic contributor to IgA nephropathy and even other CKD. The present study shed light on MTR as a genetic second hit factor of development of IgA nephropathy. Several advantages of the present study were as follows: (i) a large number of the gene polymorphisms assessed in a candidate gene approach, (ii) stringent adjustment for the family-wise error rate by the method of Bonferroni and (iii) controlling the substantial clinical differences between the patients with IgA nephropathy and non-CKD patients using the multivariate regression models and, more rigorously, the matching design.
Although multiple studies identified gene polymorphisms associated with the development of IgA nephropathy [5, 9] , premature characterization of the control participants and insufficient analyses might draw biased conclusions. Since the majority of previous studies included self-reported healthy participants as the control, the patient with IgA nephropathy had an obviously higher level of proteinuria and probably lower level of eGFR compared with the control participants. Consequently, the gene polymorphisms identified in these previous studies might contribute to proteinuria and impaired renal function. The present study deliberately described the clinical characteristics of the non-CKD control participants and carefully clarified that MTR A2756G was unlikely contributed to proteinuria and impaired renal function, suggesting that MTR A2756G was a genetic contributor to the development of IgA nephropathy. MTR A2756G might play a pivotal role in oxidative stress and affect the nephrotoxic effect of aberrantly glycosylated IgA1. Homocysteine binds to the receptor for N-methyl-D-aspartate (NMDA) and subsequently induces the local production of reactive oxygen species [39] . Although little information is available about the precise molecular effect of MTR A2756G on the serum homocysteine level, epidemiological studies revealed that major homozygote (2756AA) was associated with higher serum level of homocysteine [40] [41] [42] , strongly suggesting that MTR A2756G contributed to the serum homocysteine level. Given the MTR A2756G-regulated expression of homocysteine, the results of the present study might reflect that homocysteine-induced oxidative stress in the kidney might potentiate the nephrotoxic effect of aberrantly glycosylated IgA1, leading to the development of IgA nephropathy. MTR A2756G might potentially affect histological lesions of IgA nephropathy independently of the aberrantly glycosylated IgA1. Hyperhomocysteinemia can interestingly induce proliferation of mesangial cells and accumulation of mesangial matrix, histologically characteristic of IgA nephropathy [43] . Proliferation of mesangial cells is induced by the activation of nicotinamide adenine dinucleotoide phosphate oxidase by homocysteine, which is mediated by Rac GTPase [44] , ceramide [45, 46] and Vav2, a member of the guanine nucleotide exchange factor-Vav subfamily [47] . Hyperhomocysteinemia also induces the accumulation of mesangial matrix by increased expression of tissue inhibitor of metallpproteinase-1 [44, [46] [47] [48] and decreased expression of matrix metalloproteinase (MMP)-1 [46] [47] [48] and MMP-9 [47, 48] . These studies also suggested that homocysteine might be a candidate of second hit for the development of IgA nephropathy. Further investigation is essential to examine our hypothesis.
The present study had several limitations. First, PRE-DICT-IgAN enrolled the patients who were diagnosed with IgA nephropathy between 1990 and 2005 and visited their hospital between 2006 and 2008, suggesting that selective survivor bias might exist. This nonrandom sampling of the patients with IgA nephropathy might lead to the biased estimates of the associations between the gene polymorphisms of interest and IgA nephropathy. Second, male-predominant sampling of non-CKD participants might lead to a biased estimate of associations between gene polymorphisms of interest and development of IgA nephropathy. To control this imbalance of gender, each patient with IgA nephropathy was randomly matched with a non-CKD participant, ascertaining that MTR A2756G was persistently associated with IgA nephropathy. Third, the set of gene polymorphisms examined in the present study did not include several promising genes that were identified as genetic factors in development of IgA nephropathy in the previous large studies such as C1GALT1 [49] , IL5RA [50] and TNFRSF6B [50] . Fourth, the sample size of the present study was too small to assess associations between development of IgA nephropathy and gene polymorphisms in dominant and recessive models, although only 31 gene polymorphisms with !5% of minor homozygotes were assessed (Table 3) . Stringent adjustment for the family-wise error rate might lead to b error. ADIPOQ T94G and ACE I/D with raw P < 0.05 might also contribute to the development of IgA nephropathy as several reports suggested [51] , although larger independent study is essential. Finally, the present study assessed only an association between IgA nephropathy and gene polymorphisms. Biologically plausible mechanisms should be investigated by in vitro functional genomic studies to verify that MTR A2756G plays a pivotal role in the development of IgA nephropathy.
In conclusion, the present study carefully identified MTR A2756G as a genetic contributor to the development of IgA nephropathy, among multiple atherosclerotic diseaserelated gene polymorphisms, even after controlling stringently for family-wise error rate. These results certainly provided a new insight into the development of IgA nephropathy, although further in vitro functional genomic studies were essential to verify our hypothesis. 
